![]() Giredestrant is a highly potent, nonsteroidal, oral, SERD. Besides, the emergence of giredestrant (GDC-9545), a novel oral selective estrogen receptor degrader (SERD) drug, provided another orally administered drug option. There was also no significant difference in 3-year invasive disease-free survival (iDFS) between the two groups. 3FEC-3T) in the neoadjuvant setting for high-risk HR +/HER2 − BC patients, and found similar clinical responses between the two groups, such as residual cancer burden (RCB) rates. As mentioned at the 2020 European Society for Medical Oncology (ESMO) Annual Meeting, the NeoPAL trial ( 1) for the first time compared the efficacy of CDK4/6i in combination with letrozole versus chemotherapy (letrozole-palbociclib combination vs. Particularly, in certain patients, the emergence of a novel molecularly targeted drug named CDK4/6i has been associated with therapeutic benefits similar to those of chemotherapy. However, more and more clinical trials found that the efficacy of neoadjuvant ET was not weaker than that of chemotherapy for some HR +/HER2 − patients, with less adverse effects and good patient compliance. In the neoadjuvant setting, chemotherapy had always been the first choice. This article will briefly review and summarize these relevant progresses in early BC treatment in 2021.įor HR +/HER2 − BC patients, ET is the standard of care. Dramatic research progress has been achieved in the fields of neoadjuvant therapy and adjuvant therapy across different molecular subtypes of breast cancer, which are of significant clinical value in aiding clinical decisions. Currently, discovery and application of biological markers are urgently needed to better identify the population who would benefit from certain treatment, thus paving the way for precision medicine. Its treatment landscape has improved from the era of chemotherapy to that of immunotherapy and targeted therapy, with an abundance of exciting results from clinical trials available to guide clinical practice. In contrast to the two aforementioned BC subtypes, triple-negative breast cancer (TNBC) lacks well-defined molecular targets. The selection of HER2 − targeted therapy in the chemotherapy-free neoadjuvant setting is one of the likely future directions for exploration. The addition of TKI may be a good choice, especially when patients have achieved a poor response from dual HER2 − blockade with pertuzumab and trastuzumab (HP). Their combination with tyrosine kinase inhibitors (TKI) can theoretically inhibit HER2 signaling more comprehensively, which also have exhibited great responses in clinical trials. As for human epidermal growth factor receptor 2-positive (HER2 +) BC, HER2-targeted monoclonal antibodies such as trastuzumab in combination with chemotherapy is currently the standard of neoadjuvant therapy. Another new direction for HR+ patients is how to use polygenic risk score (PRS) to identify patients with low risk of recurrence, who could be spared from chemotherapy. Currently, escalation of ET in the postoperative period is receiving increasing attention, including the addition of CDK4/6 inhibitors (CDK4/6i), use of ovarian function suppression (OFS) in the premenopausal period, and prolonging the duration of ET, which have achieved significant therapeutic benefits. Endocrine therapy (ET) is one of the most important treatment approaches for hormone receptor positive (HR +) BC patients. Treatment for breast cancer (BC) has gradually changed from localized therapy dominated by radical mastectomy to systemic therapy based on molecular subtypes. Email: 30 March 2022 Accepted: 20 April 2022 Published: 30 April 2022. Department of Breast Cancer, Cancer Center, Guangdong Provincial People’s Hospital and Guangdong Academy of Medical Sciences, 106 Zhongshan Er Road, Guangzhou 510080, China. Policy of Dealing with Allegations of Research MisconductĬorrespondence to: Kun Wang.Policy of Screening for Plagiarism Process. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |